Echo Therapeutics, Inc. (Nasdaq: ECTE) today announced positive results from its clinical trial of the Symphony® tCGM System in major general surgery and cardiothoracic surgery for critically ill patients Continuously monitored glucose levels with Symphony® tCGM in the intensive care unit at Thomas Jefferson University Hospital in Philadelphia, ECTE’s Symphony System accurately read glucose levels with a […]
Systems America, Inc. (SYAI) announced today after market hours that company received notice that Pink OTC Markets finished the processing the Company’s 2011 Annual Report and two reports for the quarters of 2012. As the result the Pink Sheets “Current Information” tier will be applied to the SYAI on July 25, 2012. Also Systems America is […]
Galectin Therapeutics (GALT) develops carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the company’s unique approach of galectin proteins, key mediators of biologic function. Galectin announced today that it has received a notice of issuance from the U.S. Patent and Trademark Office for Patent Number 8,236,780. The patent covers key […]
Astex Pharmaceuticals, Inc. (ASTX) today announced that Janssen-Cilag International NV, who holds marketing and development rights for DACOGEN™ in all markets except the North America, was notified that the CHMP (Committee for Medical Products for Human Use) of the EMA (European Medicines Agency) granted a positive opinion recommending approval of DACOGEN™ for injection in the […]
pSivida Corp. (PSDV) today announced the National Security Agency of Medicines and Health Products (L’Agence Nationale de Sécurité du Médicament et des Produits de Santé) has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. Dr. Paul Ashton, President and […]
Somaxon Pharmaceuticals (SOMX) announced yesterday’s, after market closet, hat it has entered into separate settlement arrangements with Mylan Inc. and its subsidiary, Mylan Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc. and its subsidiary Par Pharmaceutical, Inc. to resolve pending patent litigation involving Silenor(R) 3 mg and 6 mg tablets. The settlement agreement with Mylan grants […]
StemCells, Inc. (STEM) today announced preclinical data demonstrating that its proprietary human neural stem cells restored memory and enhanced synaptic function in two animal models relevant to Alzheimer’s disease (AD). The research was conducted in collaboration with a world-renowned leader in AD, Frank LaFerla, Ph.D., Director of the University of California, Irvine (UCI) Institute for […]
Anthera Pharmaceuticals, Inc. (ANTH) stock gained today 87.24% on 23.9M shares in volume. We profiled ANTH as a potential bounce candidate right after the company’s report of the mixed results for its Phase 2b PEARL-SC clinical study in patients with systemic lupus erythematosus. Today Anthera Pharmaceuticals came out with the positive clinical data from the […]
Hovnanian Enterprises, Inc. (NYSE:HOV) and GSO Capital Partners LP (“GSO”) announced today a land banking arrangement for up to $125 million. GSO, the credit arm of The Blackstone Group (NYSE:BX), will manage funds and acquire a portfolio of land parcels from Hovnanian and option finished lots on a quarterly takedown basis back to Hovnanian. As […]
Misonix, Inc. (MSON) announced today its participation in SpineWeek 2012, in Amsterdam, Netherlands. SpineWeek takes place every four years and synchronizes the annual meetings of leading scientific societies, focused on disorders of the spine. SpineWeek had an attendance of over 2,600 individuals, including many recognized leaders in the field from all around the globe. Misonix […]
